Literature DB >> 23074422

Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model.

K Chandra, G Blackhouse, B R McCurdy, M Bornstein, K Campbell, V Costa, J Franek, K Kaulback, L Levin, S Sehatzadeh, N Sikich, M Thabane, R Goeree.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23074422      PMCID： PMC3384363     

Source DB:  PubMed          Journal:  Ont Health Technol Assess Ser        ISSN： 1915-7398


× No keyword cloud information.
  15 in total

1.  Grading quality of evidence and strength of recommendations.

Authors:  David Atkins; Dana Best; Peter A Briss; Martin Eccles; Yngve Falck-Ytter; Signe Flottorp; Gordon H Guyatt; Robin T Harbour; Margaret C Haugh; David Henry; Suzanne Hill; Roman Jaeschke; Gillian Leng; Alessandro Liberati; Nicola Magrini; James Mason; Philippa Middleton; Jacek Mrukowicz; Dianne O'Connell; Andrew D Oxman; Bob Phillips; Holger J Schünemann; Tessa Tan-Torres Edejer; Helena Varonen; Gunn E Vist; John W Williams; Stephanie Zaza
Journal:  BMJ       Date:  2004-06-19

2.  Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.

Authors:  Michael Spencer; Andrew H Briggs; Ronald F Grossman; Laureen Rance
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.

Authors:  Nicholas R Anthonisen; Melissa A Skeans; Robert A Wise; Jure Manfreda; Richard E Kanner; John E Connett
Journal:  Ann Intern Med       Date:  2005-02-15       Impact factor: 25.391

4.  Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease.

Authors:  Maureen P M H Rutten-van Mölken; Martine Hoogendoorn; Leida M Lamers
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

5.  Characterization of pulmonary rehabilitation programs in Canada in 2005.

Authors:  Dina Brooks; Rebecca Sottana; Barbara Bell; Mary Hanna; Lisanne Laframboise; Sugi Selvanayagarajah; Roger Goldstein
Journal:  Can Respir J       Date:  2007-03       Impact factor: 2.409

Review 6.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

7.  Standardised mortality rates in females and males with COPD and asthma.

Authors:  T Ringbaek; N Seersholm; K Viskum
Journal:  Eur Respir J       Date:  2005-05       Impact factor: 16.671

Review 8.  The clinical importance of dynamic lung hyperinflation in COPD.

Authors:  Denis E O'Donnell; Pierantonio Laveneziana
Journal:  COPD       Date:  2006-12       Impact factor: 2.409

9.  The cost of moderate and severe COPD exacerbations to the Canadian healthcare system.

Authors:  N Mittmann; L Kuramoto; S J Seung; J M Haddon; C Bradley-Kennedy; J M Fitzgerald
Journal:  Respir Med       Date:  2007-12-20       Impact factor: 3.415

10.  Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.

Authors:  Maureen P M H Rutten-van Mölken; Jan B Oostenbrink; Marc Miravitlles; Brigitta U Monz
Journal:  Eur J Health Econ       Date:  2007-03-17
View more
  8 in total

1.  Adherence Monitoring Using Telemonitoring Techniques.

Authors:  Sarah Dietz-Terjung; Martina Große-Suntrup; Christoph Schöbel
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 2.  Specialized community-based care: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2012-11-01

3.  Using a Health Economic Framework to Prioritize Quality Indicators: An Example With Smoking Cessation in Chronic Obstructive Pulmonary Disease.

Authors:  Austin Nam; David M J Naimark; Matthew B Stanbrook; Murray D Krahn
Journal:  MDM Policy Pract       Date:  2019-05-27

4.  Cost-Utility Analysis of Home Mechanical Ventilation in Patients with Amyotrophic Lateral Sclerosis.

Authors:  Ondřej Gajdoš; Martin Rožánek; Gleb Donin; Vojtěch Kamenský
Journal:  Healthcare (Basel)       Date:  2021-02-01

5.  The Effects of Low Pressure Domiciliary Non-Invasive Ventilation on Clinical Outcomes in Patients with Severe COPD Regardless Having Hypercapnia.

Authors:  Christiaan Theunisse; Huibert H Ponssen; Netty T C de Graaf; Maaike Scholten-Bakker; Sten P Willemsen; David Cheung
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-03-26

6.  Cost-effectiveness of integrated disease management for high risk, exacerbation prone, patients with chronic obstructive pulmonary disease in a primary care setting.

Authors:  Andrew D Scarffe; Christopher J Licskai; Madonna Ferrone; Kevin Brand; Kednapa Thavorn; Doug Coyle
Journal:  Cost Eff Resour Alloc       Date:  2022-08-12

Review 7.  The effect of domiciliary noninvasive ventilation on clinical outcomes in stable and recently hospitalized patients with COPD: a systematic review and meta-analysis.

Authors:  Janine Dretzke; David Moore; Chirag Dave; Rahul Mukherjee; Malcolm J Price; Sue Bayliss; Xiaoying Wu; Rachel E Jordan; Alice M Turner
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-09-16

8.  Is Protocolised Weaning that Includes Early Extubation Onto Non-Invasive Ventilation More Cost Effective Than Protocolised Weaning Without Non-Invasive Ventilation? Findings from the Breathe Study.

Authors:  Iftekhar Khan; Mandy Maredza; Melina Dritsaki; Dipesh Mistry; Ranjit Lall; Sarah E Lamb; Keith Couper; Simon Gates; Gavin D Perkins; Stavros Petrou
Journal:  Pharmacoecon Open       Date:  2020-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.